A Candidate Gene Approach Identifies the TRAF1/C5 Region as a Risk Factor for Rheumatoid Arthritis by Kurreeman, Fina A. S et al.
A Candidate Gene Approach Identifies
the TRAF1/C5 Region as a Risk Factor
for Rheumatoid Arthritis
Fina A. S. Kurreeman
1, Leonid Padyukov
2, Rute B. Marques
1, Steven J. Schrodi
3, Maria Seddighzadeh
2,
Gerrie Stoeken-Rijsbergen
1, Annette H. M. van der Helm-van Mil
1, Cornelia F. Allaart
1, Willem Verduyn
4,
Jeanine Houwing-Duistermaat
5, Lars Alfredsson
6, Ann B. Begovich
3, Lars Klareskog
2, Tom W. J. Huizinga
1,
Rene E. M. Toes
1*
1 Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands, 2 Rheumatology Unit, Department of Medicine, Karolinska Institute at Karolinska
Hospital, Stockholm, Sweden, 3 Celera, Alameda, California, United States of America, 4 Department of Immunohaematology and Bloodbank, Leiden University Medical
Center, Leiden, The Netherlands, 5 Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands, 6 Institute of Environmental Medicine,
Karolinska Institute, Stockholm, Sweden
Funding: This work was supported
by funds from the Dutch Arthritis
Foundation, The Netherlands
Organisation for Scientific Research
and the European Community’s FP6
funding Project 018661 Autocure.
The funders had no role in study
design, data collection and analysis,
decision to publish, or preparation
of the manuscript.
Competing Interests: Drs. Begovich
and Schrodi own stock options in
Applied Biosystems and Celera
Genomics. The remaining authors
have declared no conflicts of
interest.
Academic Editor: Cathryn Lewis,
Kings College London, United
Kingdom
Citation: Kurreeman FAS, Padyukov
L, Marques RB, Schrodi SJ,
Seddighzadeh M, et al. (2007) A
candidate gene approach identifies
the TRAF1/C5 region as a risk factor
for rheumatoid arthritis. PLoS Med
4(9): e278. doi:10.1371/journal.
pmed.0040278
Received: June 22, 2007
Accepted: August 13, 2007
Published: September 18, 2007
Copyright:  2007 Kurreeman et al.
This is an open-access article
distributed under the terms of the
Creative Commons Attribution
License, which permits unrestricted
use, distribution, and reproduction
in any medium, provided the
original author and source are
credited.
Abbreviations: ACPA, anti-
citrullinated protein antibody; CI,
confidence interval; HLA, human
leucocyte antigen; htSNP, haplotype
tagging SNP; LD, linkage
disequilibrium; OR, odds ratio; RA,
rheumatoid arthritis; RF, rheumatoid
factor; SNP, single-nucleotide
polymorphism; TNF, tumor necrosis
factor
* To whom correspondence should
be addressed. E-mail: R.E.M.Toes@
lumc.nl
ABSTRACT
Background
Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting ;1% of the population.
The disease results from the interplay between an individual’s genetic background and
unknown environmental triggers. Although human leukocyte antigens (HLAs) account for
;30% of the heritable risk, the identities of non-HLA genes explaining the remainder of the
genetic component are largely unknown. Based on functional data in mice, we hypothesized
that the immune-related genes complement component 5 (C5) and/or TNF receptor-associated
factor 1 (TRAF1), located on Chromosome 9q33–34, would represent relevant candidate genes
for RA. We therefore aimed to investigate whether this locus would play a role in RA.
Methods and Findings
We performed a multitiered case-control study using 40 single-nucleotide polymorphisms
(SNPs) from the TRAF1 and C5 (TRAF1/C5) region in a set of 290 RA patients and 254 unaffected
participants (controls) of Dutch origin. Stepwise replication of significant SNPs was performed
in three independent sample sets from the Netherlands (ncases/controls ¼ 454/270), Sweden
(ncases/controls ¼ 1,500/1,000) and US (ncases/controls ¼ 475/475). We observed a significant
association (p , 0.05) of SNPs located in a haplotype block that encompasses a 65 kb region
including the 39 end of C5 as well as TRAF1. A sliding window analysis revealed an association
peak at an intergenic region located ;10 kb from both C5 and TRAF1. This peak, defined by
SNP14/rs10818488, was confirmed in a total of 2,719 RA patients and 1,999 controls (odds
ratiocommon ¼ 1.28, 95% confidence interval 1.17–1.39, pcombined ¼ 1.40 3 10
 8) with a
population-attributable risk of 6.1%. The A (minor susceptibility) allele of this SNP also
significantly correlates with increased disease progression as determined by radiographic
damage over time in RA patients (p ¼ 0.008).
Conclusions
Using a candidate-gene approach we have identified a novel genetic risk factor for RA. Our
findings indicate that a polymorphism in the TRAF1/C5 region increases the susceptibility to
and severity of RA, possibly by influencing the structure, function, and/or expression levels of
TRAF1 and/or C5.
The Editors’ Summary of this article follows the references.
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Rheumatoid arthritis (RA) is characterized by chronic
inﬂammation and destruction of the synovial joints leading
to progressive joint damage and disability. The disease has a
complex etiology, including a wide spectrum of clinical
manifestations, variability in disease severity and/or progres-
sion, and differential response to a range of therapies. This
heterogeneous phenotype suggests the involvement of both
environmental and genetic factors [1], where the genetic
component of RA has been estimated to be between 50%–
60% [2,3]. Identiﬁcation of disease-associated genes is
important as it will guide our understanding of the biological
pathways underlying polygenic diseases and the development
of potential novel therapeutic targets.
The most prominent genetic association in RA is conﬁned
to the human leukocyte antigen (HLA) locus. Although this
association has been known for almost 30 years, and although
the underlying mechanism is still not understood, it has been
replicated in multiple studies [2,4]. The identiﬁcation of RA-
associated genes outside of the HLA region, however, has
been a challenge. Recently one such gene, protein tyrosine
phosphatase, non-receptor type 22 (lymphoid) (PTPN22),w a s
identiﬁed in the ﬁrst step of a large genetic-association study
utilizing putative functional SNPs [5]. The gene product
encoded by PTPN22 is, like the HLA locus, involved in T cell-
mediated immune responses. However, other immune com-
ponents are also thought to play a pivotal role in RA, as
demonstrated by the beneﬁcial effects of treatment with
agents that block proinﬂammatory cytokines, such as tumor
necrosis factor a (TNFa) [6]. Moreover, in several exper-
imental animal models for RA, innate immune responses
mediated by a diversity of players have been implicated in
arthritis. In this respect, a prominent role for the comple-
ment system has been identiﬁed as mice deﬁcient in
complement factors are resistant to arthritis, and as it has
been shown that targeting complement component 5 (C5) by
antibodies prevents the onset of arthritis and reduces the
clinical severity in mouse models for arthritis [7,8]. Likewise,
the observation that high levels of C5a, a potent chemo-
attractant, are found in synovial ﬂuid of RA patients
combined with the fact that C5a receptor-deﬁcient mice are
also resistant to arthritis induction, indicate a central role for
these mediators in arthritis [9,10]. A genome scan of mice that
were or were not susceptible to antibody-induced arthritis
revealed that the main genetic inﬂuence detected in this
model maps to the C5 region [11].
These functional data in mice inspired us to hypothesize
that the C5 region would be a contributing factor in RA.
Therefore, we searched for further evidence by ﬁrst address-
ing the question of whether any genetic indications exist that
implicate the involvement of this region in RA. A conven-
tional linkage study using microsatellite markers identiﬁed a
linkage peak in the vicinity of the C5 region [12]. Although
this study provided weak evidence for linkage (logarithm of
the odds score, LOD 1.8), it further boosted our interest in
this region. C5 is located next to TNF receptor-associated factor 1
(TRAF1), an essential effector of the TNF signaling cascade.
Since TNF blockade represents a powerful intervention in
both mice and humans for the treatment of arthritis, it
provided an additional rationale to explore this genetic
region encoding C5 and TRAF1, which are adjacent to each
other on Chromosome 9q33–34. We therefore sought to
investigate whether these candidate genes, which are impor-
tant immune mediators, would play a role in RA.
Methods
Study Populations
All RA patients in all sets in this study met the American
College of Rheumatology 1987 revised criteria for RA [13].
Sample set 1 cases consisted of 290 RA patients consec-
utively included from the out-patient clinic of the Leiden
University Hospital in 1994 [14] and 254 controls randomly
selected by the section Immunogenetics and Transplantation
Immunology of Leiden University Medical Center, Leiden,
The Netherlands (ITI).
Since 89% of the ﬁrst set of RA patients were rheumatoid
factor (RF) positive, we genotyped an independent sample set
2, which consisted of 454 RF-positive patients from two
inception cohorts of early arthritis patients (EAC and BEST)
and a second set of 270 randomly selected Dutch blood
donors from ITI. Brieﬂy, the EAC consists of patients
included from 1993 onwards and originating from a health
care region of about 400,000 inhabitants in the western part
of The Netherlands. General practitioners were encouraged
to refer patients directly when arthritis was suspected.
Patients were included when the symptom duration was less
than 2 y. Patients from the BEST study were recruited
between March 2000 and August 2002 at 20 centers in the
western part of The Netherlands. Patients had a maximum
disease duration of 2 y, were at least 18 y of age, and had
active disease (deﬁned as   six swollen joints,   six tender
joints, and either an erythrocyte sedimentation rate of   28
mm/h or a global health assessment score of   20 on a 100-
mm visual analog scale, where 0¼best and 100¼worst). Only
patients with a diagnosis of RA were included in the present
study. These cohorts are further described in detail in other
reports [15,16].
Sample set 3 consisted of 1,500 RA patients (70% RF-
positive) and 1,000 unaffected participants (controls) from
the Swedish EIRA study as previously described [17]. Brieﬂy,
RA patients and controls aged 18–70 y during May 1996 to
December 2003 from a geographically deﬁned area in the
south and central regions of Sweden. Control participants
were randomly selected from a continuously updated na-
tional population register, with consideration given to age,
sex, and living area. If the selected control was not traceable,
reported having RA, or refused to participate, a new control
was selected using the same procedure.
Sample set 4, obtained from the Genomics Collaborative,
(GCI), comprised 475 RF-positive RA patients and 475
individually matched controls from the US and has been
described in detail elsewhere [5]. In brief, all case samples
were from white North Americans who were RF-positive and
whose condition met the 1987 American College of Rheu-
matology diagnostic criteria for RA. Control samples were
taken from a pool of healthy white individuals with no
medical history of RA. A single control was matched to each
case on the basis of sex, age (65 y), and ethnicity (grand-
parental country/region of origin).
Patients from sample sets 1 and 4 had considerably longer
disease duration at inclusion (13.8 6 10.1 y and 11.7 6 10.0 y,
respectively) as compared to patients from sample sets 2 and
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A Novel Genetic Risk Factor for RA3( ,3 y) (Table S1). All controls were healthy unrelated white
individuals originating from the same geographical area as
the patients. There was no overlap between cases and
controls across all studies. All protocols and recruitments
were approved by national and/or local institutional review
boards, and informed written consent was obtained from all
participants.
SNP Selection and Genotyping
We chose 40 polymorphisms spanning TRAF1/C5 and their
ﬂanking genes PHD ﬁnger protein 19 (PHF19)a n dcentrosomal
protein 110 kDa (CEP110) for this study (Table 1). We selected
haplotype tagging SNPs (htSNPs) from the International
HapMap Project database (http://www.hapmap.org/index.
html) as well as random SNPs from the University of California
Santa Cruz database (http://genome.ucsc.edu/) to ascertain
maximum haplotype information for each of the genes and
intergenic regions that are likely to harbor regulatory regions.
Chromosomal locations of the SNPs were extracted from
SNPPER (http://snpper.chip.org/) Goldenpath hg17, dbSNP
build 123. Genotyping across all studies was performed as
described in detail in Protocol S1. Three of the 40 SNPs were
excluded from further analysis after reviewing results from
sample set 1, two of which (SNP13/rs4837803 and SNP27/
rs10119768) were not polymorphic and one (SNP35/rs7856420)
of which deviated from Hardy-Weinberg equilibrium.
Statistical Analysis
Single SNP and haplotype analysis. Single SNP analysis and
genetic model assessment was initially performed using SPSS
version 12.0 (SPSS, http://www.spss.com/) in sample set 1. We
did not ﬁnd evidence of a recessive model for any SNPs. Since
all SNPs were in Hardy-Weinberg equilibrium and adhered to
the additive model of association, we performed further tests
using allelic comparisons. Single- and multilocus allelic
analyses were performed using Haploview version 3.32
Table 1. Association of Candidate Gene SNPs with RA
SNP
ID
SNP rs ID Gene Location Chromosome
Location
a
Allele1/
Allele2
Susceptibility
Allele
Allele Ratios
b:
Cases, Controls
Frequency
c:
Cases, Controls
Allelic OR
(95% CI)
p-Value
1 rs1837 PHF19 39UTR/intergenic 120697783 G/A A 159:385, 110:290 0.292, 0.275 1.09 (0.81–1.47) 0.5611
2 rs12377227 PHF19 Intron 9 120706087 A/G G 74:452, 44:354 0.141, 0.111 1.32 (0.87–2.00) 0.1742
3 rs10985070 PHF19 Intron 4 120715675 A/C C 263:281, 168:236 0.483, 0.416 1.31 (1.01–1.72) 0.0387
4 rs4836834 TRAF1 Exon 8/39UTR 120745455 A/T T 260:268, 209:297 0.492, 0.413 1.38 (1.07–1.78) 0.0104
5 rs10435844 TRAF1 Intron 7 120747753 T/G G 182:304, 158:326 0.374, 0.326 1.24 (0.94–1.62) 0.1169
6 rs2239657 TRAF1 Intron 7 120751074 A/G G 207:329, 164:336 0.386, 0.328 1.29 (0.99–1.68) 0.0509
7 rs2416804 TRAF1 Intron 4 120755950 C/G G 224:228, 206:288 0.496, 0.417 1.37 (1.05–1.79) 0.0153
8 rs1014529 TRAF1 Intron 3 120764497 G/C C 208:332, 165:333 0.385, 0.331 1.26 (0.97–1.64) 0.0708
9 rs1930781 TRAF1 Intron 2 120767388 A/G G 208:332, 166:336 0.385, 0.331 1.27 (0.98–1.65) 0.0668
10 rs2416806 TRAF1 59UTR/intergenic 120769846 C/G G 214:308, 160:326 0.410, 0.329 1.42 (1.09–1.85) 0.0080
11 rs10739580 TRAF1 59UTR/intergenic 120774836 T/C C 192:314, 154:320 0.379, 0.325 1.27 (0.97–1.67) 0.0741
12 rs6478491 TRAF1 59UTR/intergenic 120778044 G/C C 8:532, 7:493 0.015, 0.014 1.06 (0.35–3.26) 0.9123
14 rs10818488 TRAF1 59UTR/intergenic 120784641 G/A A 247:255, 193:289 0.492, 0.400 1.45 (1.12–1.88) 0.0039
15 rs2416808 TRAF1 59UTR/intergenic 120785837 A/G G 247:255, 193:289 0.492, 0.400 1.45 (1.12–1.88) 0.0039
16 rs2900180 TRAF1 59UTR/intergenic 120785936 C/T T 216:332, 161:331 0.394, 0.327 1.34 (1.03–1.74) 0.0250
17 rs12377743 C5 39UTR/intergenic 120790004 G/A A 58:482, 39:461 0.107, 0.078 1.42 (0.91–2.22) 0.1032
18 rs7874632 C5 39UTR/intergenic 120792886 G/C C 4:512, 2:500 0.008, 0.004 1.95 (0.31–15.38) 0.4323
19 rs12005198 C5 39UTR/intergenic 120793949 A/G A 539:1, 501:1 0.998, 0.998 1.08 (0.00–39.38) 0.9588
20 rs7045519 C5 Intron 39 120797394 C/A A 58:482, 40:462 0.107, 0.080 1.39 (0.89–2.17) 0.1255
21 rs4310279 C5 Intron 38 120801702 A/G G 148:392, 124:374 0.274, 0.249 1.11 (0.84–1.48) 0.3587
22 rs16910233 C5 Intron 37 120803165 C/G G 4:518, 3:499 0.008, 0.006 1.28 (0.24–7.24) 0.7433
23 rs10985112 C5 Intron 32 120810962 G/A A 54:486, 33:465 0.100, 0.066 1.57 (0.98–2.52) 0.0501
24 rs7026551 C5 Intron 31 120812687 A/C C 121:393, 94:402 0.235, 0.190 1.32 (0.96–1.80) 0.0749
25 rs7037673 C5 Intron 28 120820038 C/T C 319:195, 279:219 0.621, 0.560 1.28 (0.99–1.66) 0.0508
26 rs1035029 C5 Intron 27 120822372 A/G G 206:316, 188:316 0.395, 0.373 1.10 (0.85–1.42) 0.4766
28 rs17611 C5 Exon 19 120848754 G/A G 261:187, 267:227 0.583, 0.540 1.19 (0.91–1.55) 0.1935
29 rs10116271 C5 Intron 15 120857702 C/T C 255:251, 221:263 0.504, 0.457 1.21 (0.93–1.56) 0.1362
30 rs25681 C5 Exon 13 120859559 C/T C 297:205, 265:227 0.592, 0.539 1.24 (0.96–1.61) 0.0918
31 rs993247 C5 Intron 10 120864803 A/G A 307:213, 274:226 0.590, 0.548 1.19 (0.92–1.54) 0.1717
32 rs7033790 C5 Intron 8 120867946 C/T T 129:389, 100:402 0.249, 0.199 1.33 (0.98–1.81) 0.0565
33 rs2300939 C5 Intron 1 120891271 C/T T 44:454, 34:452 0.088, 0.070 1.29 (0.79–2.11) 0.2856
34 rs1924081 C5 59UTR/intergenic 120902001 T/A A 137:413, 100:398 0.249, 0.201 1.32 (0.98–1.79) 0.0620
36 rs10818503 CEP110 Exon 1 120930324 A/G G 181:333, 144:358 0.352, 0.287 1.35 (1.03–1.78) 0.0257
37 rs10760146 CEP110 Intron 2 120936639 C/T C 332:216, 276:220 0.606, 0.556 1.23 (0.95–1.58) 0.1061
38 rs10818504 CEP110 Exon 5 120940243 C/T C 312:210, 280:226 0.598, 0.553 1.20 (0.93–1.55) 0.1504
39 rs17292952 CEP110 Exon 16 120983394 G/A G 525:25, 473:25 0.955, 0.950 1.11 (0.61–2.03) 0.7189
40 rs2038681 CEP110 Intron 25 120998594 A/C C 94:416, 74:428 0.184, 0.147 1.31 (0.92–1.85) 0.1147
Data in bold indicate significant SNPs.
aChromosomal locations were extracted from SNPPER Goldenpath hg17, dbSNP build 123.
bNumber of alleles were compared in cases versus controls: allele1:allele2 cases, allele1:allele2 controls.
cFrequency of the susceptibility allele.
doi:10.1371/journal.pmed.0040278.t001
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A Novel Genetic Risk Factor for RA(MIT, http://www.broad.mit.edu/mpg/haploview/) [18] with 40
SNPs in sample set 1 followed by six signiﬁcant SNPs in
sample set 2, the three most signiﬁcant SNPs in sample set 3,
and the single best-associating SNP in sample set 4. Odds
ratios were calculated using Epi Info v6 (CDC, http://www.cdc.
gov/epiinfo/). All p-values reported were two-sided. A p-value
, 0.05 was considered signiﬁcant. Based on the linkage
disequilibrium (LD) structure in sample set 1, haplotype
blocks were inferred under the algorithm of Gabriel et al. [19]
in Haploview 3.32. To further minimize haplotypic uncer-
tainty, we used the software TagSNPs version 1.0 (http://
www-rcf.usc.edu/;stram/tagSNPs.html) to identify eight
htSNPs from block 2 and ten htSNPs from block 3 (global
R
2
h . 98%) [20]. The R
2
h coefﬁcient is the squared
correlation between the true haplotype count (number of
copies of a haplotype) and the haplotype count predicted by
TagSNPs. We chose htSNPs so that haplotypes were predicted
with a global R
2
h value of 0.95 or above, indicating a high
accuracy. Haplotype analyses using these htSNPs were
performed in Haploview 3.32.
Global p-values for haplotype associations were calculated
usingthesoftwareHaplo.Statsversion1.2(http://mayoresearch.
mayo.edu/mayo/research/schaid_lab/software.cfm) used for
estimating haplotype effects under the generalized linear
model [21]. htSNPs from blocks 2 and 3 in sample set 1 were
further investigated by sliding-window analysis in Haploview
3.32 to determine the basis of the associated haplotypes.
Combining datasets. Odds ratios (OR)s from all sample sets
were combined by the random model of the Cochran-Mantel-
Haenszel test as implemented in EasyMA [22]. A Breslow-Day
test of between-stage heterogeneity was also performed in
EasyMA to test for consistency across sample sets [23]. We
observed evidence of heterogeneity for SNP rs4836834 at p ,
0.05 (Table S2).
Logistics regression. Forward conditional logistics regres-
sion was performed using all six signiﬁcant SNPs from sets 1
and 2 in SPSS 12.0. Genotypes were coded as categorical
variables 0, 1, and 2 with the nonassociated genotype as
reference. No evidence of a recessive effect was observed, as
detailed in Table S3.
Population attributable risk. Population-attributable risk
(PAR) was calculated using the population prevalence of the
exposure (P) and the relative risk associated with the
exposure (R), as follows [24].
PAR ¼
PðR   1Þ
1 þ PðR   1Þ
Autoantibodies
Baseline laboratory parameters included IgM-RF (ELISA)
and IgG-ACPA (ELISA, Immunoscan RA Mark2, Euro-
Diagnostica, http://www.eurodiagnostica.com/). The cut-off
for antibody positivity was set according to the manufac-
turer’s instructions. Since baseline ACPA status was not
available for most samples from the BEST study, we restricted
our analysis to the EAC and EIRA cohorts. Autoantibody (RF
and ACPA) and genotype status were available from 419
patients from the EAC (we additionally genotyped RF-
negative and ACPA-negative patients in this cohort) and
1,395 patients from the EIRA study.
Severity
Radiographs of hands and feet were scored at baseline and
2y( n¼278) using the Sharp–van der Heijde method (erosions
and joint space narrowing of hands and feet) [25]. Data was
available from 193 A carriers (AAþAG) and 85 non-A carriers
(GG) from the EAC cohort. The prevalence of either RF (A
carriers 60.9%, non-A carriers 56.5%, p ¼ 0.485) or anti-
citrullinated protein antibodies (ACPA) (A carriers 60.7%,
non-A carriers 60.8%, p ¼ 0.986) is not signiﬁcantly different
between the two groups analyzed. Differences in means
between groups were calculated using sharp scores adjusted
for baseline with a two-sided nonparametric Mann-Whitney
test.
Transcription Factor Binding Sites
Transcription factor binding sites (TFBSs) were predicted
using MAPPER (http://bio.chip.org/mapper/mapper-main), a
platform that combines information from two well-known
TFBS databases, TRANSFAC and JASPAR. The prediction is
generated from a hidden Markov model and is based on
experimentally determined binding sites in multiple genomes
[26].
Results
The TRAF1/C5 Region Associates with RA
To investigate whether the TRAF1/C5 region on Chromo-
some 9q33–34 associates with RA, we selected a total of 40
polymorphisms spanning these candidates and their ﬂanking
genes for genotyping. Tagging SNPs as well as random SNPs
were included to ascertain maximum haplotype information
for each of the genes and to ensure coverage of intergenic
regions which may harbor regulatory polymorphisms.
Single SNP analysis performed in the ﬁrst set of RA
patients (n ¼ 290) and controls (n ¼ 254) revealed signiﬁcant
association between six SNPs in the TRAF1/C5 region (SNPs 4,
7, 10, 14, 15, and 16) and RA (p ¼ 0.0104, 0.0153, 0.0080,
0.0039, 0.0039, and 0.0250, respectively) (Table 1). One SNP in
PHF19 (SNP3/rs10985070) and one in CEP110 (SNP36/
rs10818503) also showed moderate association with RA (p ¼
0.0387 and 0.0257, respectively). None of the SNPs inves-
tigated showed evidence of a recessive mode of association.
To delineate the haplotypic architecture, we estimated the
underlying haplotype block structure of the 32 SNPs with
minor allele frequency . 5% in the controls. We identiﬁed a
potential recombination spot at SNP3/rs10985070 and
SNP24/rs7026551 that divides the region into three inher-
itance blocks, blocks 1, 2, and 3. Block 1 is 8 kb and
encompasses the 39 end to intron 9 of PHF19; block 2 extends
from TRAF1 through 24 kb of intergenic sequence to exon 32
of C5; while block 3 (178 kb) contains the remainder of the C5
gene and CEP110 (Figure 1A). The LD structure in the Dutch
population was similar to the structure reported by the
International HapMap Project (unpublished data).
To further minimize haplotypic uncertainty and to identify
the minimal combination of SNPs that provide maximum
information content within each block, we scanned these two
blocks independently using the software TagSNPs. In block 2
we identiﬁed a minimal set of eight htSNPs with a global R
2
h
of 0.996, and in block 3 we found ten htSNPs with an R
2
h of
0.985, indicating that haplotypes can be inferred with .95%
certainty. Haplotypes were predicted, and analyses from all
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A Novel Genetic Risk Factor for RAFigure 1. LD Structure and Haplotype Association across the TRAF1/C5 Region in Sample Set 1 (290 RA Patients and 254 Controls)
(A) Haplotype block structure was predicted on the basis of the strength of pairwise LD, which is presented as a 232 matrix; red represents very high LD
(D’), white indicates absence of correlation between SNPs, and blue indicates high correlation with a low level of significance. SNPs that were chosen for
haplotype analysis are indicated along the top by an asterisk.
(B) Using htSNPs from each block, indicated by the asterisk in (A), haplotypes were inferred with a certainty of above 98% as represented by the R
2
h
value.
¥Comparisons were made between one haplotype versus all others in cases and controls.
aThe protective haplotype that is significantly less
frequent in cases.
bThe susceptible haplotype that is significantly more frequent in patients.
(C) Sliding window of the susceptible haplotype using consecutive two-SNP combinations of the htSNPs reveals that SNP14 and SNP15 account for
most of the association observed. For each of the SNP pairs we show the –log10 p-value. The dotted line indicates a nominal p-value of 0.005.
doi:10.1371/journal.pmed.0040278.g001
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A Novel Genetic Risk Factor for RAblocks revealed that the association with RA was restricted to
SNPs in block 2 (Figure 1B), as demonstrated by the global p-
value of association (p , 0.05) and suggesting the possible
involvement of TRAF1 and/or the 39 end of C5. Of the four
common haplotypes capturing . 95% of the variation, two
signiﬁcantly associated haplotypes were observed, one in-
creased in RA patients (susceptible haplotype
b p¼0.039), and
one over-represented in controls (protective haplotype
a p ¼
0.012). By applying a two-marker sliding window analysis, we
observed a signiﬁcant peak centered on SNP14/rs10818488
and SNP15/rs2416808 (p ¼ 0.0039) (Figure 1C). Using three-
and ﬁve-marker windows did not alter the outcome, suggest-
ing that the signiﬁcance seen with the other TRAF1 SNPs
(Table 1) may be due to LD. To explore this possibility, we
analyzed the r
2-values with respect to SNP14. We conﬁrmed
that the most signiﬁcant SNPs, which are located in TRAF1
and the adjacent intergenic region, are highly correlated with
SNP14 (r
2 . 0.90) (Figure 2).
Replication in Three Independent Sample Sets from The
Netherlands, Sweden, and the US
Six tagging SNPs which were signiﬁcant (p , 0.05) in the
initial study were selected for replication in a fully
independent set of Dutch cases and controls (sample set 2).
Of these, only SNP14/rs10818488 and SNP15/rs2416808 were
statistically signiﬁcant (p , 0.05). Haplotype and a two-
marker sliding window analysis localized the strongest region
of association to SNP14 and SNP15, conﬁrming the results
from sample set 1 (unpublished data). Combined analyses of
the data from sample sets 1 and 2 showed an even stronger
association for SNP14 (OR 1.34, 95% conﬁdence interval [CI]
1.13–1.58; p¼5.56310
 4) and SNP15 (OR 1.33, 95% CI 1.13–
1.57; p¼6.65310
 4) (Table 2). Although the other four SNPs
did not reach statistical signiﬁcance in sample set 2, they were
highly signiﬁcant in the combined analysis (Table 2). To
evaluate putative modes of inheritance, we calculated
genotype-speciﬁc ORs in the combined dataset as detailed
in Table S3. All SNPs were consistent with an additive model.
On the basis of forward conditional logistics regression,
SNP14 remained in the model with a heterozygote (AG) OR of
1.38 (95% CI 1.04–1.83, p¼0.027) and a homozygote (AA) OR
of 2.06 (95% CI 1.42–2.98, p ¼ 1.29 3 10
 3).
Similar replication of three SNPs in a cohort of Swedish
patients and controls (sample set 3) conﬁrmed association
with SNP14/rs10818488 (p ¼ 0.0078) (Table 2). A combined
analysis of patients and controls of European origin (Dutch
and Swedish) with 2,244 RA patients and 1,524 controls
(sample sets 1, 2, and 3) showed that the most signiﬁcant
associations could again be attributed to SNP14 (OR 1.24,
95% CI 1.11–1.38, p ¼1.73 310
 5) and SNP15/rs2416808 (OR
1.23, 95% CI 1.09–1.40, p ¼ 7.21 3 10
 5) (Table 2). Addition-
ally, these ﬁndings were further replicated in a case-control
sample set from the US. Since LD analysis in the original
three sample sets showed SNP14 and SNP15 to be highly
correlated (r
2 . 0.98) we genotyped only SNP14 and
conﬁrmed that the minor susceptibility allele was associated
with RA risk (OR 1.36, 95% CI 1.13–1.64; p¼0.001) (Table 2).
Combined analysis of SNP14 in all four independent sets
(ncases/controls ¼ 2,719/1,999) yielded a highly signiﬁcant
association ORcommon¼1.26, 95% CI 1.15–1.37, pcombined ¼
1.40 3 10
 8) and a PAR of 6.1% (95% CI 4.0–8.5).
Association with Autoantibody-Positive Disease
RA is a heterogeneous disease with a considerable variation
in phenotype as evidenced by the fact that some patients are
autoantibody-positive whereas others are not. Antibodies to
citrullinated protein antigens, called ACPAs, have gained
much interest as current data suggest that ACPA-positive and
negative RA may have different genetic risk factors [27]. To
investigate whether the TRAF1/C5 region is associated with a
speciﬁc phenotype of RA, we next stratiﬁed patients for
autoantibody status from whom baseline ACPA and RF
measurements were available (n ¼ 1,814) Interestingly,
SNP14/rs10818488 mainly predisposes to autoantibody-pos-
itive disease when compared to controls (OR 1.25, 95% CI
1.11–1.40, p ¼ 2.27 3 10
 4) (Figure 3A). Although we also
observed an increase in the frequency of the A allele in
autoantibody-positive as compared to autoantibody-negative
disease, this difference did not reach formal statistical
signiﬁcance (OR 1.15, 95% CI 0.98–1.34, p ¼ 0.0789). These
data therefore suggest that the current genetic risk factor
may be predominant in the autoantibody-positive subset of
RA patients.
Association with Severity
Because the clinical course of RA can vary considerably
ranging from nonerosive disease to rapidly progressive joint
damage, we also analyzed whether the SNPs in the TRAF1/C5
region were involved with RA progression. Annual X-rays of
the hands and feet of patients were assigned Sharp–van der
Heijde units, a combined score for bone erosions and joint
space narrowing. Carriers of the minor susceptibility allele of
SNP14/rs10818488 had an almost 2-fold higher severe disease
course at 2 y after inclusion as compared to the non-A
carriers (Figure 3B; mean 6 SE score of A carriers/non-A
carriers, 11.4 6 1.4/7.1 6 1.8; p ¼ 0.008) indicating that the A
allele predisposes not only to RA susceptibility, but also to
severity.
SNP14/rs10818488 Is Located in a TFBS
To investigate the potential functional effect of this SNP,
we scanned for transcription factor binding sites using
Figure 2. RA-Associated SNPs are Highly Linked to SNP14
Pairwise LD (r
2) between associated SNP14/rs10818488 and all other
SNPs genotyped was calculated. For each of the SNPs listed along the x-
axis we show the –log10 (y-axis) of the p-values for RA patients versus
controls. Dotted lines indicate a nominal p-value of 0.005 and a maximal
r
2 value of 1. In a logistics regression model, only SNP14/rs10818488
remained statistically significant (p ¼ 6.16 3 10
 4)
doi:10.1371/journal.pmed.0040278.g002
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A Novel Genetic Risk Factor for RAMAPPER [26]. The SNP14 susceptibility A allele encodes a
potential binding site for EP300, a histone acetyl transferase
that regulates transcription via chromatin remodeling. In the
absence of this allele, the binding of EP300 to this region is
predicted to be disrupted, potentially disturbing the epige-
netic tag for transcriptional activation. We hypothesize that
this putative transcription factor binding site may be
involved in the regulation of the neighboring TRAF1 and/or
C5 gene.
Discussion
Using a candidate-gene approach, we identiﬁed the TRAF1/
C5 region on Chromosome 9q33–34 as a susceptibility and
severity factor for RA. This region was also associated with
RA in a large-scale genetic association study (Schrodi et al.,
unpublished data). It is, therefore, intriguing to see that these
independent studies, in which the process leading to results
differed, give similar results, and in doing so provide strong
evidence for the TRAF1/C5 region as a true RA-associated
genetic variant. The recent genome-wide study performed by
the Wellcome Trust failed to identify this region as a
candidate for RA [28]. Although it is difﬁcult to speculate
why this region was not detected in the Wellcome Trust Case
Control Consortium study, we do note that none of the SNPs
showing strong association in our hands was genotyped by the
Wellcome Trust. Additionally, in line with our ﬁnding that
this genetic risk factor is predominant in the autoantibody-
positive subgroup, substratiﬁcations of the speciﬁc RA
phenotypes may be needed to detect signiﬁcant association.
The protein encoded by TRAF1 is a member of the TNF
receptor-associated factor (TRAF) protein family, which
associates with and mediates the signal transduction from
various receptors of the TNF receptor superfamily, including
the receptor for TNFa [29]. In addition to a direct role in
TNFa signaling, TRAF1 has also been implicated in the
activation and proliferation of T cells [30] and is expressed
ubiquitously by other cells of the immune system including
monocytes and B cells [31]. It is therefore possible that
TRAF1 could play a role in RA by aiding the maintenance of
the proinﬂammatory environment. Likewise, studies have
also shown that perpetuation of inﬂammation coincides with
increased levels of the anaphylatoxin C5a in the synovial ﬂuid
of RA patients [9]. Further studies in mice identifying C5 as a
candidate gene and showing that C5 deﬁciency results in
lower incidence and less-severe disease course support the
Table 2. Association of Significant SNPs in Four Independent Sample Sets
SNP Set 1 (Netherlands) Set 2 (Netherlands) Sets 1 þ 2
Allele Ratios
a
Cases, Controls
Allelic OR
(95% CI)
p-
Value
Allele Ratios
a
Cases, Controls
Allelic OR
(95% CI)
p-
Value
Allele Ratios
a
Cases, Controls
Allelic OR
(95% CI)
b
p-
Value
SNP4/rs4836834 260:268, 209:297 1.38 (1.07–1.78) 0.0104 378:432, 225:301 1.17 (0.93–1.47) 0.1626 638:700, 434:598 1.41 (0.96–2.13) 0.078
SNP7/rs2416804 224:228, 206:288 1.37 (1.05–1.79) 0.0153 369:415, 224:300 1.19 (0.95–1.50) 0.1242 593:643, 430:588 1.27 (1.07–1.50) 0.006
SNP10/rs2416806 214:308, 160:326 1.42 (1.09–1.85) 0.0080 296:489, 180:340 1.14 (0.90–1.45) 0.2559 510:798, 340:666 1.26 (1.02–1.56) 0.029
SNP14/rs10818488 247:255, 193:289 1.45 (1.12–1.88) 0.0039 387:425, 220:304 1.26 (1.00–1.58) 0.0419 634:680, 413:593 1.34 (1.13–1.58) 5.56 3 10
 4
SNP15/rs2416808 247:255, 193:289 1.45 (1.12–1.88) 0.0039 387:425, 221:303 1.25 (0.99–1.57) 0.0494 634:680, 414:592 1.33 (1.13–1.58) 6.65 3 10
 4
SNP36/rs10818503 181:333, 144:358 1.35 (1.03–1.78) 0.0257 259:527, 166:352 1.04 (0.82–1.33) 0.7329 440:860, 310:710 1.17 (0.98–1.40) 0.210
SNP Set 3 (Sweden) Sets 1 þ 2 þ 3
Allele Ratios
a
Cases, Controls
Allelic OR
(95% CI)
p-
Value
Allele Ratios
a
Cases, Controls
Allelic OR
(95% CI)
b
p-
Value
SNP4/rs4836834 — — — — — —
SNP7/rs2416804 — — — — — —
SNP10/rs2416806 1,212:1,756, 677:1,089 1.11 (0.98–1.25) 0.0893 1,722:2,554, 1,017:1,755 1.18 (1.03–1.34) 0.015
SNP14/rs10818488 1,500:1,500, 840:984 1.17 (1.04–1.32) 0.00781 2,134:2,180, 1,253:1,577 1.23 (1.12–1.36) 1.73 3 10
 5
SNP15/rs2416808 1,351:1,353, 772:890 1.15 (1.02–1.30) 0.0241 1,985:2,033, 1,186:1,482 1.23 (1.09–1.40) 7.21 3 10
 5
SNP36/rs10818503 — — — — — —
SNP Set 4 (US) Sets 1 þ 2 þ 3 þ 4
Allele Ratios
a
Cases, Controls
Allelic OR
(95% CI)
p-
Value
Allele Ratios
a
Cases, Controls
Allelic OR
(95% CI)
b
p-
Value
SNP4/rs4836834 — — — — — —
SNP7/rs2416804 — — — — — —
SNP10/rs2416806 — — — — — —
SNP14/rs10818488 427:513, 356:582 1.36 (1.13–1.64) 0.00102 2,561:2,693, 1,609:2,159 1.26 (1.15–1.37) 1.40 3 10
 8
SNP15/rs2416808 — — — — — —
SNP36/rs10818503 — — — — — —
Data in bold indicate the p-value of the most significant SNPs.
aThe allele frequencies between allele1:allele2 in cases was compared to allele1:allele2 in controls. Allele 1 refers to the susceptibility allele from Table 1.
bMantel-Haenzel OR as calculated under the random model. Raw data can be obtained from Table S2.
doi:10.1371/journal.pmed.0040278.t002
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A Novel Genetic Risk Factor for RArole of this gene in inﬂammation [7,11]. It is therefore likely
that although the primary function of the complement system
is to protect the host from microorganisms, a deregulated
activity of its central component, C5, can play a substantial
role in inﬂammatory diseases as well.
In order to capture the variation within these candidate
genes and potential regulatory regions, we genotyped both
SNPs that were intragenic and those located 59 and 39 of the
genes. Interestingly, the strongest replicated association was
observed with SNP14/rs10818488, which maps to an inter-
genic region ;10 kb from both TRAF1 and C5 and is present
in a TFBS, which may regulate the transcriptional activity of
its neighboring genes. However, formal testing of all known
variation within this locus, both genetic and biological, will be
necessary to pinpoint the precise biological process that is
altered by the RA-associated variant(s) present in this region.
We found a strong association of this region in all four
independent sample sets which represent varying disease
durations (,3t o.10 y) as well as a correlation with disease
progression. More importantly, these phenotypic data on
joint destruction not only indicate that the TRAF1/C5 region
predisposes to RA, but also suggest that within the RA
population, patients harboring the minor susceptibility allele
of SNP14/rs10818488 tend to experience a more severe
disease course. Although the above ﬁndings most likely
exclude the possibility of a spurious association, especially
since each case group was assigned an ethnically and
geographically matched control group, background levels of
population stratiﬁcation as described by Cardon et al. [32]
may exist in the different populations under study. It is
therefore conceivable that the slight variation in the observed
effect between the four populations may partially be due to
varying sample sizes and background levels of population
admixture.
Figure 3. The A Allele of SNP14 Is Associated with Distinct Phenotypes of RA
(Top, table) The frequency of the A allele of patients from whom baseline autoantibody status (ACPA and RF) were available was calculated. ORs and p-
values were calculated between each subgroup and controls, and indicated a predominantly higher frequency of the A allele in ACPA- and RF-positive
patients.
(Bottom, bar graph) Progression of joint damage in Sharp–van der Heijde units (‘‘Sharp score’’) is higher in the presence of the minor A allele of SNP14.
Radiological data of 193 A carriers and 85 non-A carriers were available, and differences between the groups were calculated based on disease severity
after 2 y corrected for baseline.
doi:10.1371/journal.pmed.0040278.g003
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A Novel Genetic Risk Factor for RARA is a common complex disease that results from the
interaction of multiple genetic variants, each with relatively
low penetrance, with an array of environmental triggers [33].
In advance of a genetic proﬁle that can accurately pinpoint
individuals at risk, identiﬁcation of these genetic variants can
provide insight into the underlying mechanisms of disease
and the speciﬁc pathways associated with disease induction
and/or progression. Understanding the function of these
common disease-associated variants will be important to
identify potential targets for intervention strategies that
could prove useful to all patients, whether or not they carry
the disease-associated variant.
In summary, this study provides robust evidence from four
independent sample sets (two of Dutch origin, one of Swedish
descent, and one from the US) that genetic variants within
the TRAF1/C5 region are associated with RA, indicating a
possible role for these immune-related genes in the biological
process underlying RA disease pathogenesis.
Limitations of This Study
Our study deﬁnes the TRAF1/C5 as a novel genetic region
present in the human genome that predisposes to RA.
However, the causative variation (SNP) or the biological
mechanism explaining this association is not yet known.
Although it could be that the current identiﬁed polymor-
phism is causative, other proxies in high LD with this SNP
could also be responsible for the observed association, an
issue that can be addressed in more detailed by functional
studies. Furthermore, although our data indicate a predom-
inant association with autoantibody-positive disease, our
study is underpowered to exclude the possibility that the
TRAF1/C5 region also predisposes to autoantibody-negative
disease. By combining information obtained from other
cohorts in which both the autoantibody and the TRAF1/C5
status are known, this question should be resolved in the
future. As it has been indicated that distinct genetic risk
factors underlie either autoantibody-positive or autoanti-
body-negative disease, such additional information would
provide more detailed knowledge on the genetic hetero-
geneity of these two distinct phenotypes of RA.
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Editors’ Summary
Background. Rheumatoid arthritis is a very common chronic illness that
affects around 1% of people in developed countries. It is caused by an
abnormal immune reaction to various tissues within the body; as well as
affecting joints and causing an inflammatory arthritis, it can also affect
many other organs of the body. Severe rheumatoid arthritis can be life-
threatening, but even mild forms of the disease cause substantial illness
and disability. Current treatments aim to give symptomatic relief with
the use of simple analgesics, or anti-inflammatory drugs. In addition,
most patients are also treated with what are known as disease-modifying
agents, which aim to prevent joint damage. Rheumatoid arthritis is
known to have a genetic component. For example, an association has
been shown with the part of the genome that contains the human
leukocyte antigens (HLAs), which are involved in the immune response.
Information on other genes involved would be helpful both for
understanding the underlying cause of the disease and possibly for
the discovery of new treatments.
Why Was This Study Done? Previous work in mice that have a disease
similar to human rheumatoid arthritis has identified a number of possible
candidate genes. One of these genes, complement component 5 (C5) is
involved in the complement system—a primitive system within the body
that is involved in the defense against foreign molecules. In humans the
gene for C5 is located on Chromosome 9 close to another gene involved
in the inflammatory response, TNF receptor-associated factor 1 (TRAF1).A
preliminary study in humans of this region had shown some evidence,
albeit weak, to suggest that this region might be associated with
rheumatoid arthritis. The authors set out to look in more detail, and in a
larger group of individuals, to see if they could prove this association.
What Did the Researchers Do and Find? The researchers took 40
genetic markers, known as single-nucleotide polymorphisms (SNPs),
from across the region that included the C5 and TRAF1 genes. SNPs have
each been assigned a unique reference number that specifies a point in
the human genome, and each is present in alternate forms so can be
differentiated. They compared which of the alternate forms were present
in 290 patients with rheumatoid arthritis and 254 unaffected participants
of Dutch origin. They then repeated the study in three other groups of
patients and controls of Dutch, Swedish, and US origin. They found a
consistent association with rheumatoid arthritis of one region of 65
kilobases (a small distance in genetic terms) that included one end of the
C5 gene as well as the TRAF1 gene. They could refine the area of interest
to a piece marked by one particular SNP that lay between the genes.
They went on to show that the genetic region in which these genes are
located may be involved in the binding of a protein that modifies the
transcription of genes, thus providing a possible explanation for the
association. Furthermore, they showed that one of the alternate versions
of the marker in this region was associated with more aggressive disease.
What Do These Findings Mean? The finding of a genetic association is
the first step in identifying a genetic component of a disease. The
strength of this study is that a novel genetic susceptibility factor for RA
has been identified and that the overall result is consistent in four
different populations as well as being associated with disease severity.
Further work will need to be done to confirm the association in other
populations and then to identify the precise genetic change involved.
Hopefully this work will lead to new avenues of investigation for therapy.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040278.
  Medline Plus, the health information site for patients from the US
National Library of Medicine, has a page of resources on rheumatoid
arthritis
  The UK’s National Health Service online information site has
information on rheumatoid arthritis
  The Arthritis Research Campaign, a UK charity that funds research on
all types of arthritis, has a booklet with information for patients on
rheumatoid arthritis
  Reumafonds, a Dutch arthritis foundation, gives information on
rheumatoid arthritis (in Dutch)
  Autocure is an initiative whose objective is to transform knowledge
obtained from molecular research into a cure for an increasing number
of patients suffering from inflammatory rheumatic diseases
  The European league against Rheumatism, an organisation which
represents the patient, health professionals, and scientific societies of
rheumatology of all European nations
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